ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2018
The economic impact of multiple sclerosis to the patients and their families in Norway.
Article in The European journal of health economics : HEPAC : health economics in prevention and care, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Pooled it
- A Comprehensive and Structured Follow-Up for Persons With Multiple Sclerosis (CoreDISTparticipation) to Optimize Physical Functions, Health, and Employment: Protocol for a Prospective, Single-Blinded Randomized Controlled Trial and Health Economic Evaluation.JMIR research protocols · 2025Article
- Article
- Mild multiple sclerosis challenges shape work experiences, affect self-concept, and are often trivialized despite disclosure.Frontiers in rehabilitation sciences · 2025Article
- Explaining the burden of cultural factors on MS disease: a qualitative study of the experiences of women with multiple sclerosis.BMC women's health · 2024Article
- Disease Burden and Costs Associated with Multiple Sclerosis in China: A Cross-sectional Analysis of Nationwide Survey Data.Neuroscience bulletin · 2024Article
- Economic Burden of Multiple Sclerosis Drugs in Iran during 2011-2019.Iranian journal of public health · 2023Article
- Estimation the medical cost of multiple sclerosis in Iran; 2019-2020.BMC health services research · 2022Article
- Cost-of-illness trajectories among people with multiple sclerosis by comorbidity: A register-based prospective study in Sweden.Multiple sclerosis journal - experimental, translational and clinicalArticle
- Status for and associations between disability, employment, barriers for work and health-related quality of life in individuals with multiple sclerosis: A cross-sectional study.Multiple sclerosis journal - experimental, translational and clinicalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultiple sclerosis (MS) imposes high economic costs on society, but the patients and their families have to bear some of these costs.
objectiveWe aimed to estimate the magnitude of these economic costs in Norway.
methodWe collected data through a postal questionnaire survey targeting 922 MS patients in Hordaland County, western Norway, in 2013-2014; 546 agreed to participate and were included. The questionnaire included clinical and demographic characteristics, volume and cost of MS-related resource use, work participation, income, government financial support, and disability status.
resultsThe mean annual total economic costs for the patients and their families were €11,603. Indirect costs accounted for 66% and were lower for women than for men. The direct costs were nearly identical for men and women. The costs increased up to Expanded Disability Status Scale score 6 except for steps between 3 and 4 where it remained nearly constant. The costs reduced from EDSS 6 to 8, and increased from 8 to 9. Lifetime costs ranged from €24,897 to €70,021 for patients with late disease onset and slow progression, and between €441,934 and €574,860 for patients with early onset and rapid progression.
conclusionThe economic costs of MS impose a heavy burden on the patients and their families. Supplementing the information on the cost of MS to society, our finding should be included as background information in decisions on reimbursing and allocating public resources for the well-being of MS patients and their families.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.